Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540993 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,734
- Enrollment target
NCT02540993: Completed Phase 3 study, sponsored by Bayer.
NCT02540993 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 5,734 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (643% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02540993, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,734 participants
- Enrollment target
Study Summary
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.
Primary Outcome
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,734 participants |
| Start Date | 2015-09-17 |
| Est. Completion | 2020-04-14 |
| Phase | Phase 3 |
What the finished NCT02540993 record still lists
NCT02540993 is an interventional study that assigns participants to a tested intervention. Its 5,734 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (643% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02540993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02540993 about?
NCT02540993 is a clinical study titled "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease". The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glo...
What is the current status of trial NCT02540993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,734 participants. The study started on 2015-09-17. Estimated completion is 2020-04-14.
What interventions are being tested in trial NCT02540993?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT02540993?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02540993's enrollment target sits among peer trials
5,734 42nd of 2000 higher than 1,959 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT05636176 · 5,600 participants · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI